ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

resiquimod

Also written as “BDB-001 injection”, “EIK1001” and “BDB-001 Injection”.

Its studies are mostly in Neoplasms · Neoplasm Metastasis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · COVID-19 · Hidradenitis Suppurativa, led by 2 companies.

Drug pageBDB001: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 26, 202014 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Staidson (Beijing) Biopharmaceuticalsits history only81 open or runningphase 3since Jun 26, 2020Jun 26, 2020Apr 16, 2027phase 3 · NCT07168161
Eikon Therapeutics63 open or runningphase 3since Nov 18, 2024Feb 28, 2018Dec 2026phase 2 · NCT06246110

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eikon Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2018First study: phase 1 study in NeoplasmsFirst studyNCT03486301 · 87 enrolled · United States
  2. Dec 9, 2019Named resiquimodINNProposed as its International Nonproprietary Name in WHO's List 122 · before, EIK1001, BDB001
  3. Dec 10, 2019Phase 1 study in NeoplasmsNCT04196530 · 40 enrolled · United States
  4. Jan 18, 2021Phase 2 study in NeoplasmsNCT04819373 · 1 enrolled · United States
  5. Jan 30, 2024Phase 2 study in Neoplasm MetastasisNCT06246110 · 70 enrolled · United States
  6. Nov 18, 2024Phase 3 study in Neoplasm MetastasisNCT06697301 · 740 planned · United States, Australia, Austria and more
  7. Jan 22, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07365319 · 750 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in Neoplasm MetastasisNCT06246110
  2. Dec 2035Primary completion: phase 3 study in Neoplasm MetastasisNCT06697301
  3. Dec 31, 2035Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07365319

TargetBeta

TLR7 →TLR8 →read by rule
“The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, ”NCIt, by rule
“Toll-like receptor 8 agonist; Toll-like receptor 7 agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312

Studies

All 6 Eikon Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07365319Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingDec 31, 2035750
NCT06697301Neoplasm Metastasis · United States, Australia, Austria and more3RecruitingDec 2035740
NCT06246110Neoplasm Metastasis · United States2Active, not recruitingDec 202670
NCT04819373Neoplasms · United States2CompletedApr 1, 20231
NCT04196530Neoplasms · United States1CompletedJul 31, 202440
NCT03486301Neoplasms · United States1CompletedMar 31, 202487

How it is read

Names in the registry

  • “BDB-001 injection”, 7 entries
  • “EIK1001”, 3 entries
  • “BDB-001 Injection”, 3 entries
  • “BDB001 (EIK1001)”, 2 entries
  • “BDB001”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.